NCT00857571终止1 期
An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Pfizer
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Pharmacokinetics: Cmax, AUCinf
研究概览
简要总结
The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female volunteers.
- •Female volunteers have to be of non-childbearing potential
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- •Any condition possibly affecting drug absorption (eg, gastrectomy).
- •A positive urine drug screen.
研究组 & 干预措施
Suspension
Experimental
PF-02413873 suspension
干预措施: 150 mg Suspension (Drug)
Suspension
Experimental
PF-02413873 suspension
干预措施: 30 mg Suspension (Drug)
Suspension
Experimental
PF-02413873 suspension
干预措施: 400 mg Suspension (Drug)
Suspension
Experimental
PF-02413873 suspension
干预措施: 5 mg Suspension (Drug)
Suspension
Experimental
PF-02413873 suspension
干预措施: 750 mg Suspension (Drug)
Tablet
Experimental
PF-02413873 Phase 2 Tablets
干预措施: 150 mg Tablet (Drug)
Tablet
Experimental
PF-02413873 Phase 2 Tablets
干预措施: 30 mg Tablet (Drug)
Tablet
Experimental
PF-02413873 Phase 2 Tablets
干预措施: 400 mg Tablet (Drug)
Tablet
Experimental
PF-02413873 Phase 2 Tablets
干预措施: 5 mg Tablet (Drug)
Tablet
Experimental
PF-02413873 Phase 2 Tablets
干预措施: 750 mg Tablet (Drug)
结局指标
主要结局
Pharmacokinetics: Cmax, AUCinf
时间窗: June - July 2009
次要结局
- Tmax, Tlag, AUClast, AUCt, t½, Frel.(June-July 2009)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult ParticipantsHealthyNCT00886093Pfizer10
已完成
1 期
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or ObeseOverweightObesityNCT05677867Pfizer20
已完成
1 期
OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTSHealthyNCT03871439Pfizer10
已完成
1 期
A Study Of Three PF-05190457 Formulations In Healthy VolunteersDiabetes Mellitus, Type 2NCT01522807Pfizer16
已完成
1 期
A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The BodyHuman Immunodeficiency Virus (HIV)NCT01045317Pfizer10